Belzutifan: First Approval

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome associated with multiple tumor types.
• Hypoxia-inducible factor (HIF)-2α plays a key role in the pathogenesis of VHL disease-associated tumors.
• Current treatment options for VHL-associated tumors are limited, especially for those not requiring immediate surgery.

Purpose of the Study:

• To summarize the development milestones of belzutifan, an oral HIF-2α inhibitor.
• To highlight the first FDA approval of belzutifan for specific VHL disease-associated tumors.
• To provide an overview of ongoing clinical studies for belzutifan in other indications.

Main Methods:

• Review of preclinical and clinical development data for belzutifan.
• Analysis of regulatory submission and approval process for belzutifan.
• Summary of published and ongoing clinical trials involving belzutifan.

Main Results:

• Belzutifan (Welireg™) received FDA approval in August 2021 for specific VHL-associated tumors (RCC, CNS haemangioblastomas, pNET) not requiring immediate surgery.
• Belzutifan is an oral small molecule inhibitor targeting HIF-2α.
• Ongoing studies are evaluating belzutifan in other cancers like clear cell renal cell carcinoma (ccRCC) and phaeochromocytoma/paraganglioma.

Conclusions:

• Belzutifan represents a significant advancement in targeted therapy for VHL disease.
• The approval of belzutifan provides a new therapeutic option for patients with specific VHL-associated tumors.
• Further research will continue to explore the efficacy and safety of belzutifan in various oncological settings.